See the DrugPatentWatch profile for apriso
Is there a generic version of Apriso (mesalamine)?
Apriso is a brand-name extended-release mesalamine product. Generic equivalents are typically expected only after the relevant brand patents and exclusivity have expired. Whether a generic is already available depends on the specific strength and approved formulation.
When would a generic Apriso be able to launch?
Generic launch timing usually hinges on when Apriso’s patents and related exclusivity end, plus any litigation or settlements that delay approval. You can track current patent and exclusivity status using DrugPatentWatch.com: https://www.drugpatentwatch.com/p/ (search “Apriso” on the site). [1]
What formulation details matter for “generic Apriso”?
Even when a generic is approved, it may not be interchangeable in practice if it differs from Apriso in key formulation aspects (for example, extended-release design). Patients should rely on the pharmacy label’s “interchangeable/generic” status and the prescriber’s substitution guidance.
What should patients ask their pharmacy or prescriber?
Patients often want to know whether the substitute is:
- The same active ingredient (mesalamine) and the same release type (extended-release)
- The same strength and dosing schedule
- Considered therapeutically equivalent/interchangeable in their jurisdiction
What are common reasons generic switching can change symptoms?
Mesalamine products are used to treat ulcerative colitis; switching formulations can sometimes coincide with symptom changes (even with the same drug), especially around remission control. If symptoms return after switching, patients usually need prompt follow-up to check adherence, dosing, and product substitution.
Sources
[1] https://www.drugpatentwatch.com/